FDA: Don’t Rely On Device Labeling To ‘Design Out’ Product Risks
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers shouldn’t make the mistake of using product labeling to mitigate device risks, according to a recent FDA draft guidance. Instead, firms should “design out” those risks to ensure that they only make quality products, an agency official says.
You may also be interested in...
Regulatory News In Brief
Minnesota device makers petition FDA. Invacare lays off workers following FDA consent decree. More regulatory news.
Home-Use Device Guidance Outlines Design, Labeling Considerations
Design of devices for home use should take into account the “large range of physical, sensory, cognitive and emotional capabilities and disabilities” home users may have, the FDA draft document recommends. Comments are due March 12.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?